We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Safety and Effectiveness Study of the VEGA UV-A System for Cross-linking in Eyes With Keratoconus and Ectasia

This study has been terminated.
ClinicalTrials.gov Identifier:
First Posted: July 21, 2011
Last Update Posted: March 4, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Topcon Medical Systems, Inc.
The purpose of this research study is to evaluate the long tern safety and effectiveness of cross-linking in eyes with keratoconus and ectasia.

Condition Intervention Phase
Keratoconus and Ectasia Drug: Riboflavin Device: VEGA UV-A Illumination System Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: Long Term Safety and Effectiveness of the VEGA UV-A System for Corneal Collagen Cross-Linking in Eyes With Keratoconus or Post-Refractive Corneal Ectasia

Resource links provided by NLM:

Further study details as provided by Topcon Medical Systems, Inc.:

Primary Outcome Measures:
  • Changes in Corneal Curvature [ Time Frame: 24 MO ]

Enrollment: 500
Study Start Date: December 2010
Study Completion Date: July 2012
Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: CXL Treatment
All eyes to be treated with riboflavin and UV light
Drug: Riboflavin
Riboflavin is a solution that will be delivered to the treatment area
Device: VEGA UV-A Illumination System
This is a portable electronic device designed to deliver a dose of UV-A light to the treatment area


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   12 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 12 years of age or older
  • Diagnosis of Keratoconus or Ectasia
  • Central or Inferior steepening on the Pentacam map
  • Topography consistent with Keratoconus or Ectasia
  • BSCVA 20/20 or worse
  • Removal of contact lenses for required period of time
  • Signed written informed consent
  • Willingness and ability to comply with schedule for follow up visits

Exclusion Criteria

  • For Keratoconus, a history of previous corneal surgery
  • Corneal pachymentry equal to or greater and 400
  • Previous ocular condition in the eyes to be treated that may predispose the eye for future complications
  • A history of chemical injury or delayed healing
  • Pregnancy
  • A known sensitivity to the study medications
  • Nystagmus or any other condition that would prevent a steady gaze during treatment or other diagnostic tests
  • Presence or history of any other condition or finding that makes the patient unsuitable as a candidate
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01398852

United States, Arizona
Barnet Dulaney Perkins Eye Center
Phoenix, Arizona, United States
United States, Georgia
Woolfson Eye Institute
Atlanta, Georgia, United States
United States, Massachusetts
Massachusetts Eye And Ear Infirmary
Boston, Massachusetts, United States
United States, Minnesota
Minnesota Eye Consultants
Bloomington, Minnesota, United States
United States, New York
Laser and Corneal Surgery Assoc. PC
New York, New York, United States, 10022
Mt Sinai Hospital
New York, New York, United States
Pamel Vision & Laser Group
New York, New York, United States
United States, Ohio
Cleveland Clinic-Cole Eye Institute
Cleveland, Ohio, United States, 44195
ReVision Advanced Laser Eye Center
Columbus, Ohio, United States, 43240
OSU Department of Ophthalomogy
Columbus, Ohio, United States
United States, Texas
Dell Laser Consultants
Austin, Texas, United States
Slade and Baker Vision Center
Houston, Texas, United States
United States, Utah
The Eye Institute of Utah
Salt Lake City, Utah, United States, 84107
Sponsors and Collaborators
Topcon Medical Systems, Inc.
  More Information

Responsible Party: Topcon Medical Systems, Inc.
ClinicalTrials.gov Identifier: NCT01398852     History of Changes
Other Study ID Numbers: CXL-003
First Submitted: July 11, 2011
First Posted: July 21, 2011
Results First Submitted: December 13, 2012
Results First Posted: March 4, 2013
Last Update Posted: March 4, 2013
Last Verified: December 2012

Additional relevant MeSH terms:
Dilatation, Pathologic
Corneal Diseases
Eye Diseases
Pathological Conditions, Anatomical
Vitamin B Complex
Growth Substances
Physiological Effects of Drugs
Photosensitizing Agents
Dermatologic Agents